PIVAT
LIVE

Serial Number

87331894

Owner

Pillar Biosciences, Inc.

Attorney

Andrew T. Pettit

First Use Date

Feb 9, 2018

Filing Date

Feb 10, 2017

Add to watchlist:

No watchlists yet
View on USPTO

PIVAT Trademark

Serial Number: 87331894 • Registration: 5509369

PIVAT is a trademark filed by Pillar Biosciences, Inc. on February 10, 2017. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Pillar Biosciences, Inc. (17 trademarks)

Natick, MA 01760

Entity Type: 03

Trademark Details

Filing Date

February 10, 2017

Registration Date

July 3, 2018

First Use Anywhere

February 9, 2018

First Use in Commerce

February 9, 2018

Published for Opposition

August 15, 2017

Goods & Services

computer software for the collection, management, and analysis of data for use in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; computer software for analyzing biological samples; computer software for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; computer software for use with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; computer software for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing

Collection, management, and analysis of data in the field of medical diagnostics; providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the diagnosis and treatment of cancer; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of medical diagnostics

Software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; software as a service (Saas), namely, hosting non-downloadable computer software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; collection, management, and analysis of data in the fields of scientific research, clinical research and scientific diagnostics; providing biological sample testing services for others in the fields of scientific research, clinical research and scientific diagnostics; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, and scientific diagnostics research; providing bioinformatics and gene expression microarray image analysis services for others, namely, performing gene expression quantification, gene image processing, and gene information processing for others

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Dec 6, 2024 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Dec 6, 2024 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 6, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Jun 27, 2024 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 3, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Jul 3, 2018 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 31, 2018 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 30, 2018 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 8, 2018 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 27, 2018 AITU
USE AMENDMENT FILED
Apr 10, 2018 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 10, 2018 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 10, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 15, 2017 NPUB
PUBLISHED FOR OPPOSITION
Aug 15, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 26, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 10, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 22, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 22, 2017 CRFA
ASSIGNED TO LIE
Jun 15, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 23, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 9, 2017 GNRN
NON-FINAL ACTION E-MAILED
May 9, 2017 GNRT
NON-FINAL ACTION WRITTEN
May 9, 2017 CNRT
ASSIGNED TO EXAMINER
May 6, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 16, 2017 NWOS
NEW APPLICATION ENTERED
Feb 14, 2017 NWAP